Together, these findings evidence that miR-16-5p overexpression promotes HER2-positive tumorigenesis, and apparently impairs the efficacy of the combination therapy of pyrotinib and chrysin, which provides new insights into targeting miR-16-5p for the treatment of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.